FIG 1.
Flow diagram for the STATICE Trial. aOne patient was excluded from the efficacy analysis by ICR owing to no measurable lesion. HER2, human epidermal growth factor receptor2; ICR, independent central review; IHC, immunohistochemistry; T-DXd, trastuzumab deruxtecan.